Intravenous versus subcutaneous EPO: anything to do with pure red cell aplasia complication.
Chow
Kai Ming
KM
Szeto
Cheuk Chun
CC
Li
Philip Kam-Tao
PK
D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous / Q000009:adverse effects / Q000379:methods; D007279:Injections, Subcutaneous / Q000009:adverse effects / Q000379:methods; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000209:etiology*
D011994:Recombinant Proteins; D004921:Erythropoietin